Dr. Wierda on Immunotherapy Agents for Patients With CLL

William G. Wierda, MD, PhD
Published: Tuesday, May 31, 2016

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).

Chimerica-antigen receptor (CAR) T-cell therapies are being investigated in clinical trials for patients with CLL, Wierda explains. 

Checkpoint inhibitor monoclonal antibodies, which have shown promise and activity in patients with solid tumors, are also being studied in ongoing trials, he adds. Immune manipulation and modulation is a very active area of interest and is a part of oingoing research in CLL.
William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses immunotherapy agents being explored in patients with chronic lymphocytic leukemia (CLL).

Chimerica-antigen receptor (CAR) T-cell therapies are being investigated in clinical trials for patients with CLL, Wierda explains. 

Checkpoint inhibitor monoclonal antibodies, which have shown promise and activity in patients with solid tumors, are also being studied in ongoing trials, he adds. Immune manipulation and modulation is a very active area of interest and is a part of oingoing research in CLL.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x